Sennidin ACAS# 641-12-3 |
- Sennidin B
Catalog No.:BCN6355
CAS No.:517-44-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 641-12-3 | SDF | Download SDF |
| PubChem ID | 92826 | Appearance | Yellow powder |
| Formula | C30H18O10 | M.Wt | 538.46 |
| Type of Compound | Anthraquinones | Storage | Desiccate at -20°C |
| Solubility | Soluble in chloroform and methanol; insoluble in water | ||
| Chemical Name | (9R)-9-[(9R)-2-carboxy-4,5-dihydroxy-10-oxo-9H-anthracen-9-yl]-4,5-dihydroxy-10-oxo-9H-anthracene-2-carboxylic acid | ||
| SMILES | C1=CC2=C(C(=C1)O)C(=O)C3=C(C2C4C5=C(C(=CC=C5)O)C(=O)C6=C4C=C(C=C6O)C(=O)O)C=C(C=C3O)C(=O)O | ||
| Standard InChIKey | JPMRHWLJLNKRTJ-FGZHOGPDSA-N | ||
| Standard InChI | InChI=1S/C30H18O10/c31-17-5-1-3-13-21(15-7-11(29(37)38)9-19(33)25(15)27(35)23(13)17)22-14-4-2-6-18(32)24(14)28(36)26-16(22)8-12(30(39)40)10-20(26)34/h1-10,21-22,31-34H,(H,37,38)(H,39,40)/t21-,22-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Sennidin A in combination with necrosis inducing drugs/therapies may generate synergetic tumoricidal effects on solid malignancies by means of primary debulking and secondary cleansing process. 2. Sennidin A stimulates glucose incorporation in the phosphatidylinositol 3-kinase (PI3K)- and Akt-dependent in rat adipocytes, but in the IR/IRS1-independent manner. 3. Sennidin A, has two hydroxyanthraquinone-like moieties, exerts inhibition on NS3 helicase with IC50 values of 0.8 uM. |
| Targets | Akt | GLUT | PI3K | HCV |
Sennidin A Dilution Calculator
Sennidin A Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8571 mL | 9.2857 mL | 18.5715 mL | 37.143 mL | 46.4287 mL |
| 5 mM | 0.3714 mL | 1.8571 mL | 3.7143 mL | 7.4286 mL | 9.2857 mL |
| 10 mM | 0.1857 mL | 0.9286 mL | 1.8571 mL | 3.7143 mL | 4.6429 mL |
| 50 mM | 0.0371 mL | 0.1857 mL | 0.3714 mL | 0.7429 mL | 0.9286 mL |
| 100 mM | 0.0186 mL | 0.0929 mL | 0.1857 mL | 0.3714 mL | 0.4643 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- H-Ala(3-pyridyl)-OH.HCl
Catalog No.:BCC3321
CAS No.:64090-98-8
- Cannabispirol
Catalog No.:BCN4609
CAS No.:64052-90-0
- GANT 58
Catalog No.:BCC1587
CAS No.:64048-12-0
- Ro 04-5595 hydrochloride
Catalog No.:BCC7234
CAS No.:64047-73-0
- Z-D-Pro-OH
Catalog No.:BCC2752
CAS No.:6404-31-5
- Boc-ε-Acp-OH
Catalog No.:BCC3205
CAS No.:6404-29-1
- Boc-Nle-OH
Catalog No.:BCC3296
CAS No.:6404-28-0
- Boc-Lys(Ac)-OH
Catalog No.:BCC3411
CAS No.:6404-26-8
- Torachrysone 8-O-glucoside
Catalog No.:BCN4181
CAS No.:64032-49-1
- 4(15)-Oppositene-1,7-diol
Catalog No.:BCN4180
CAS No.:640289-58-3
- Tamgermanetin
Catalog No.:BCN7944
CAS No.:640235-90-1
- Paroxetine maleate
Catalog No.:BCC7265
CAS No.:64006-44-6
- Alternariol
Catalog No.:BCN7147
CAS No.:641-38-3
- Allomatrine
Catalog No.:BCN2368
CAS No.:641-39-4
- 5-hydroxy-canthin-6-one
Catalog No.:BCN7910
CAS No.:64118-73-6
- Di-O-methylcrenatin
Catalog No.:BCN4608
CAS No.:64121-98-8
- Longistylin C
Catalog No.:BCN4182
CAS No.:64125-60-6
- Sedanolide
Catalog No.:BCN8338
CAS No.:6415-59-4
- Nilotinib(AMN-107)
Catalog No.:BCC3643
CAS No.:641571-10-0
- Echinoynethiophene A
Catalog No.:BCN4183
CAS No.:64165-98-6
- 5-Acetyl-2-(1-hydroxy-1-methylethyl)benzofuran
Catalog No.:BCN7488
CAS No.:64165-99-7
- 30-Oxolupeol
Catalog No.:BCN6673
CAS No.:64181-07-3
- trans-2,3-Dihydro-3-hydroxyeuparin
Catalog No.:BCN6922
CAS No.:64185-57-5
- Z-Hyp-Ome
Catalog No.:BCC3258
CAS No.:64187-48-0
Necrosis targeted combinational theragnostic approach using radioiodinated Sennidin A in rodent tumor models.[Pubmed:24931286]
Oncotarget. 2014 May 30;5(10):2934-46.
Residual cancer cells and subsequent tumor relapse is an obstacle for curative cancer treatment. Tumor necrosis therapy (TNT) has recently been developed to cause residual tumor regression or destruction. Here, we exploited the avidity of the Sennidin A (SA) tracer and radioiodinated SA ((1)(3)(1)I-SA) to necrotic tumors in order to further empower TNT. We showed high uptake and prolonged retention of SA in necrotic tumors and a quick clearance in other non-targeted tissues including the liver. On SPECT-CT images, tumor mass appeared persistently as a hotspot. Based on the prominent targetability of (1)(3)(1)I-SA to the tumor necrosis, we designed a combinational theragnostic modality. The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) was used to cause massive tumor necrosis, which formed the target of (1)(3)(1)I-SA that subsequently killed the residual tumor cells by cross-fire irradiation of beta particles. Consequently, (1)(3)(1)I-SA combined with CA4P significantly inhibited tumor growth, extended tumor doubling time and prolonged mean animal survival. In conclusion, (1)(3)(1)I-SA in combination with necrosis inducing drugs/therapies may generate synergetic tumoricidal effects on solid malignancies by means of primary debulking and secondary cleansing process.
Sennidin stimulates glucose incorporation in rat adipocytes.[Pubmed:16603199]
Life Sci. 2006 Aug 8;79(11):1027-33.
A novel small molecule compound which exerts insulin mimetic is desirable. Dozens of natural products that have quinone, naphthoquinone, or anthraquinone structure, were tested by a glucose incorporation assay. We found that Sennidin A, anthraquinone derivative, stimulated glucose incorporation to near level of maximal insulin-stimulated and sennidin B, a stereoisomer of Sennidin A, also stimulated, but the activity of sennidin B was lower than Sennidin A. Sennidin A-stimulated glucose incorporation was completely inhibited by wortmannin. Sennidin A did not induce tyrosine phosphorylation of insulin receptor (IR) and insulin receptor substrate-1 (IRS-1), but induced phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Our results suggest that in rat adipocytes, Sennidin A stimulates glucose incorporation in the phosphatidylinositol 3-kinase (PI3K)- and Akt-dependent, but in the IR/IRS1-independent manner.
Isolation of a human intestinal anaerobe, Bifidobacterium sp. strain SEN, capable of hydrolyzing sennosides to sennidins.[Pubmed:8161172]
Appl Environ Microbiol. 1994 Mar;60(3):1041-3.
A strictly anaerobic bacterium capable of metabolizing sennosides was isolated from human feces and identified as Bifidobacterium sp., named strain SEN. The bacterium hydrolyzed sennosides A and B to sennidins A and B via Sennidin A and B 8-monoglucosides, respectively. Among nine species of Bifidobacterium having beta-glucosidase activity, only Bifidobacterium dentium and B. adolescentis metabolized sennoside B to sennidin B, suggesting that the sennoside-metabolizing bacteria produce a novel type of beta-glucosidase capable of hydrolyzing sennosides to sennidins.
Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase.[Pubmed:26262613]
Int J Mol Sci. 2015 Aug 7;16(8):18439-53.
Hepatitis C virus (HCV) is an important etiological agent of severe liver diseases, including cirrhosis and hepatocellular carcinoma. The HCV genome encodes nonstructural protein 3 (NS3) helicase, which is a potential anti-HCV drug target because its enzymatic activity is essential for viral replication. Some anthracyclines are known to be NS3 helicase inhibitors and have a hydroxyanthraquinone moiety in their structures; mitoxantrone, a hydroxyanthraquinone analogue, is also known to inhibit NS3 helicase. Therefore, we hypothesized that the hydroxyanthraquinone moiety alone could also inhibit NS3 helicase. Here, we performed a structure-activity relationship study on a series of hydroxyanthraquinones by using a fluorescence-based helicase assay. Hydroxyanthraquinones inhibited NS3 helicase with IC50 values in the micromolar range. The inhibitory activity varied depending on the number and position of the phenolic hydroxyl groups, and among different hydroxyanthraquinones examined, 1,4,5,8-tetrahydroxyanthraquinone strongly inhibited NS3 helicase with an IC50 value of 6 microM. Furthermore, hypericin and Sennidin A, which both have two hydroxyanthraquinone-like moieties, were found to exert even stronger inhibition with IC50 values of 3 and 0.8 microM, respectively. These results indicate that the hydroxyanthraquinone moiety can inhibit NS3 helicase and suggest that several key chemical structures are important for the inhibition.
